Antenatal Screening: Catching Depression and Anxiety Before Birth

Prenatal Prevalence

The clinical framing of perinatal mood disorders as primarily "postpartum" conditions undersells their prenatal burden. Depression affects approximately 12 to 13 percent of women during pregnancy (ACOG Practice Bulletin 343, 2023). Anxiety disorders -- including GAD, panic disorder, and OCD -- affect approximately 15 to 20 percent of pregnant women (Fawcett et al., JAMA Psychiatry, 2019). Many of these patients have symptoms that predate pregnancy and are exacerbated by hormonal changes, obstetric uncertainty, and the psychological demands of anticipated parenthood.

The clinical relevance of prenatal mental health extends beyond the patient's current experience:

• Prenatal depression is one of the strongest predictors of postpartum PMAD (Howard et al., Lancet, 2014)
• Untreated prenatal anxiety is associated with preterm birth, low birth weight, and impaired fetal neurodevelopment (Staneva et al., Midwifery, 2015)
• Antenatal PMAD reduces adherence to prenatal care, including prenatal vitamins, gestational diabetes management, and appointment attendance
• Early identification allows treatment to be established prenatally, positioning the patient much better for the postpartum period

Waiting until the postpartum visit to screen misses the window in which prenatal intervention can modify the postpartum trajectory.

---

ACOG Screening Recommendations

ACOG Practice Bulletin 343 (2023) recommends:

• Screening for depression and anxiety at least once during the prenatal period using a validated instrument
• The EPDS is the endorsed tool for prenatal screening
• Screening is recommended at both early and late pregnancy to capture onset at different gestational stages
• Women with risk factors (prior psychiatric history, prior PMAD, history of abuse or trauma, limited social support, stressful life events) should be screened more frequently

This is a minimum standard. The clinical evidence supports more frequent prenatal screening, particularly given the high prevalence of prenatal anxiety and the predictive value of prenatal scores for postpartum outcomes.

---

Recommended Prenatal Screening Schedule

| Timing | Rationale | |---|---| | First trimester intake (8 to 12 weeks) | Baseline assessment; captures pre-existing conditions exacerbated by pregnancy | | Second trimester (18 to 22 weeks) | Midpoint check; catches de novo onset; particularly relevant for patients with anatomy scan anxiety | | Third trimester (30 to 34 weeks) | Predicts postpartum risk; allows treatment establishment before delivery | | Any visit with clinical concern | Positive symptoms, significant stressor, obstetric complication, disclosure by patient |

For patients with prior PMAD, bipolar history, or significant first-trimester elevation: monthly prenatal screening is appropriate.

---

The EPDS in Pregnancy: Validation and Interpretation

The EPDS was originally validated in postpartum populations, but extensive psychometric research has validated its use in pregnancy. At a threshold of 10 or above, the EPDS performs comparably in pregnant samples to its postpartum performance.

One prenatal consideration: item 1 ("I have been able to laugh and see the funny side of things") and item 2 ("I have looked forward with enjoyment to things") may be affected by normal first-trimester ambivalence or first-time parent anxiety about the upcoming delivery rather than anhedonia. Clinical interview supplements the score.

Antenatal EPDS thresholds

| Score | Clinical action | |---|---| | 0 to 9 | Routine monitoring; reassess per schedule | | 10 to 12 | Elevated risk; brief clinical inquiry; assess stressors, support, sleep; rescreening in 4 weeks | | 13 and above | Probable major depression; refer to perinatal mental health provider | | Any item 10 above 0 | Direct safety assessment; refer regardless of total score |

---

Risk Stratification

Not all pregnant patients carry the same PMAD risk. Identifying elevated-risk patients allows for more intensive monitoring and proactive referral before symptoms are severe.

High-risk clinical indicators:

• Prior PMAD or major depressive episode
• Prior suicide attempt
• History of bipolar disorder or psychosis
• History of trauma (childhood, domestic violence, prior pregnancy loss, prior traumatic birth)
• Active substance use or recent cessation
• Unplanned or unwanted pregnancy
• History of infertility or treatment
• Significant social isolation (no partner, no family support, recent relocation)
• Obstetric complications: preterm labor, hyperemesis gravidarum, gestational diabetes, fetal anomaly diagnosis
• Immigrant or refugee status (elevated rates of isolation, cultural stigma, lack of native-language support)
• Prior traumatic birth

Any patient presenting with one or more of these factors warrants enhanced screening intensity, a lower threshold for referral, and proactive discussion of mental health support resources at the first prenatal visit.

---

Obstetric Complications as PMAD Triggers

Several obstetric complications carry particular PMAD risk beyond the baseline elevated risk that pregnancy itself creates.

Hyperemesis gravidarum (HG)

Severe nausea and vomiting causing weight loss, dehydration, and functional impairment is associated with significantly elevated prenatal depression and anxiety, and with PTSD related to the HG experience itself. Patients with HG are frequently isolated, physically suffering, and unable to maintain normal activities including prenatal care appointments. Screen specifically at any HG-related visit. Mood symptoms may improve with HG treatment but should be reassessed throughout.

Preterm labor and cervical insufficiency

Patients on activity restriction, receiving cerclage, or hospitalized for preterm labor prevention face profound loss of autonomy and significant fear of infant loss. This is a high-anxiety clinical context that should trigger screening and low-threshold referral. Anxiety, specifically peritraumatic distress around the threat of pregnancy loss, is the predominant PMAD in this group.

Fetal anomaly diagnosis

Receiving a diagnosis of a major fetal anomaly -- particularly following amniocentesis or specialized ultrasound -- produces an acute grief and traumatic stress response for many families. Clinical management typically focuses on obstetric options counseling, genetics consultation, and pediatric subspecialty coordination. Mental health needs in these families are often not formally assessed. A social work or perinatal mental health referral should be part of the standard fetal anomaly care pathway.

Recurrent pregnancy loss

Patients with documented RPL (two or more pregnancy losses) carry significantly elevated anxiety in subsequent pregnancies, regardless of current pregnancy viability. Many develop a clinical picture that includes hypervigilance, avoidance of bonding, and intrusive thoughts about loss that meets criteria for PTSD or OCD. The EPDS score alone will not capture the full clinical picture. Direct inquiry about these specific experiences is appropriate.

---

Prenatal Treatment Considerations

Psychotherapy

Cognitive behavioral therapy (CBT) and interpersonal therapy (IPT) have the strongest evidence base for prenatal depression and anxiety. Both are compatible with pregnancy without any pharmacological considerations. For anxiety presentations, CBT with behavioral components (exposure, behavioral activation) is first-line. For relational or grief-based presentations, IPT is appropriate.

The recommendation for therapy should be clear and specific: "I'm recommending that you start working with a perinatal mental health therapist now, during pregnancy, rather than waiting until after delivery. Starting therapy prenatally is associated with better outcomes in the postpartum period."

Pharmacology

The decision to initiate or continue psychiatric medication in pregnancy is a risk-benefit discussion that should involve the patient, the OB, and ideally a perinatal psychiatrist or PMH-C certified provider with pharmacology knowledge. The risks of untreated prenatal depression and anxiety to fetal development and maternal health must be weighed against the risks of specific medications.

Sertraline and other SSRIs have a significant safety record in pregnancy. The ACOG Committee Opinion on Psychiatric Medication Use During Pregnancy (2023) supports individualized decision-making rather than blanket avoidance of psychotropic medication in pregnancy.

For patients currently on psychiatric medication who become pregnant or who are planning pregnancy: do not recommend discontinuation without psychiatric consultation. Abrupt discontinuation of SSRIs and SNRIs carries significant risk of discontinuation syndrome and mental health deterioration.

---

Documenting Prenatal Screening

EPDS scores obtained prenatally should be documented in the chart with the same care as postpartum scores:

• Tool used, score, date
• Clinical interpretation
• Item 10 status
• Referral or watchful waiting decision
• Follow-up plan

Prenatal scores also provide retrospective context when postpartum PMAD is identified. A clinician reviewing a postpartum emergency can see whether the patient had an elevated prenatal EPDS and what the response was. This documentation shapes continuity and -- in adverse outcome scenarios -- demonstrates clinical diligence.

---

For referral pathways from prenatal identification through warm handoff and into ongoing perinatal mental health care, see our article on care coordination and warm handoffs in perinatal mental health. For a complete comparison of screening tools used in both antenatal and postpartum settings, see our EPDS vs. PHQ-9 vs. GAD-7 comparison for perinatal providers.